top of page

The Paris Saclay Cancer Cluster commits to teaching cancer immunotherapy at École Polytechnique affiliated with the Institut Polytechnique de Paris (IP Paris)

The Paris-Saclay Cancer Cluster (PSCC) is pleased to announce a strengthened partnership with École Polytechnique to offer cutting-edge teaching on cancer immunotherapy. As part of this initiative, Eric Vivier, President of the PSCC, and Frédéric Vély, technological platform expert of the cluster, were respectively appointed Professor and Master Lecturer at École Polytechnique, founding school of the Institut Polytechnique de Paris ( IP Paris), also a founding member of the PSCC. From the first quarter of 2025, they will be responsible for teaching cancer immunotherapy to 3rd year engineering students, biology option. They will bring to École Polytechnique their in-depth knowledge of immunology and oncology, as well as their experience in the research and development of innovative therapies against cancer.


A collaboration that consolidates the links between the Paris-Saclay Cancer Cluster (PSCC), the École Polytechnique, the Institut Polytechnique de Paris (IP Paris), Innate Pharma and the biotech companies in the cluster.

By committing to the training of engineering students, the PSCC and its president demonstrate their desire to promote synergy between the academic world, research and industry to promote innovation.

With the main mission of accelerating the development of new therapeutic solutions against cancer in France, the biocluster sees in this teaching of cancer immunotherapy at the École Polytechnique an opportunity to strengthen the ecosystem and establish new partnerships to accelerate value creation in the field of oncology.



Stimulate connections between the academic world and the industrial sector, to bring out new talents and start-ups in oncology.

Through this teaching provided by PSCC experts, the biocluster will establish close links with the student community, thus facilitating their integration into the industrial environment, taking advantage of its proximity to biotechs and innovative start-ups from the ecosystem.

For example, Innate Pharma, the first biotech to join the PSCC, already welcomes students from IP Paris, while other start-ups in the PSCC ecosystem are also seeking to attract new talent.

By exposing students to its vast network, the PSCC opens the way to entrepreneurship and promotes the emergence of innovators who could subsequently benefit from specialized training to realize their business projects in the field of oncology.


Professor Eric Vivier explains:To invent the oncology of tomorrow, we must create bridges between all these actors! By bringing together researchers, students and industrialists working on the same subject, we create fertile ground. Generating these synergies to spark innovation and facilitate the development of promising projects is what drives me! »



Eric Vivier DVM, Ph.D

· Doctor of veterinary medicine and holder of a doctorate in immunology.

· University professor - hospital practitioner at Aix-Marseille University (AMU), where he directs the innate lymphoid cell laboratory at the Marseille-Luminy Immunology Center (CIML).

· Co-founder and scientific director of Innate Pharma, a biotechnology company specializing in the development of cancer immunotherapies.

· President of the Paris-Saclay Cancer Cluster

· Member of the National Academy of Medicine

· Member of EMBO (European Molecular Biology Organization).

· ERC (European Research Council) laureate.

Frédéric Vély, PharmD, Ph. D

· Doctor of Pharmacy and PhD in Immunology.

· Lecturer - hospital practitioner at Aix-Marseille University (AMU), where he directs the Immunological Profiling Platform of the Immunopole of Marseille.

· Technological platform expert at Paris-Saclay Cancer Cluster


bottom of page